HC Wainwright Forecasts TC Biopharm FY2024 Earnings

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) – HC Wainwright issued their FY2024 earnings per share estimates for TC Biopharm in a report issued on Friday, December 6th. HC Wainwright analyst forecasts that the company will post earnings of ($0.01) per share for the year. HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for TC Biopharm’s current full-year earnings is ($0.01) per share. HC Wainwright also issued estimates for TC Biopharm’s FY2025 earnings at $0.00 EPS.

TC Biopharm Stock Performance

Shares of TCBP opened at $0.63 on Monday. TC Biopharm has a 52-week low of $0.44 and a 52-week high of $56.02. The company has a 50-day simple moving average of $2.30 and a 200-day simple moving average of $5.61. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.67.

TC Biopharm Company Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.